Characterization of CD22 expression in acute lymphoblastic leukemia

Pediatric Blood & Cancer
Nirali N ShahAlan S Wayne

Abstract

CD22 is a B-lineage differentiation antigen that has emerged as a leading therapeutic target in acute lymphoblastic leukemia (ALL). Properties of CD22 expression relevant to therapeutic targeting were characterized in primary samples obtained from children and young adults with relapsed and chemotherapy refractory B-precursor (pre-B) ALL. CD22 expression was demonstrated in all subjects (n = 163) with detection on at least 90% of blasts in 155 cases. Median antigen site density of surface CD22 was 3,470 sites/cell (range 349-19,653, n = 160). Blasts from patients with known 11q23 (MLL) rearrangement had lower site density (median 1,590 sites/cell, range 349-3,624, n = 20 versus 3,853 sites/cell, range 451-19,653, n = 140; P = <0.0001) and 6 of 21 cases had sub-populations of blasts lacking CD22 expression (22%-82% CD22 +). CD22 expression was maintained in serial studies of 73 subjects, including those treated with anti-CD22 targeted therapy. The levels of soluble CD22 in blood and marrow by ELISA were low and not expected to influence the pharmacokinetics of anti-CD22 directed agents. These characteristics make CD22 an excellent potential therapeutic target in patients with relapsed and chemotherapy-refractory ALL, although ca...Continue Reading

References

Jan 1, 1997·Annual Review of Immunology·T F TedderJ H Kehrl
Oct 18, 2005·Advances in Immunology·Thomas F TedderKaren M Haas
Oct 13, 2006·The New England Journal of Medicine·Kevin C OeffingerUNKNOWN Childhood Cancer Survivor Study
Jul 4, 2008·Blood·Kakushi MatsushitaRobert J Kreitman
Aug 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elizabeth A RaetzUNKNOWN Children's Oncology Group Pilot Study
Dec 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yujian Zhang, Ira Pastan
Oct 21, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard H KoMignon L Loh
Mar 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alan S WayneIra Pastan
Sep 28, 2010·Cytometry. Part B, Clinical Cytometry·Gregory A JasperMaryalice Stetler-Stevenson
Oct 1, 2011·Blood Reviews·Dieter Hoelzer, Nicola Gökbuget
Nov 10, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rajat SinghRobert J Kreitman
Feb 23, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J KreitmanIra Pastan
Mar 27, 2013·The New England Journal of Medicine·Stephan A GruppCarl H June

❮ Previous
Next ❯

Citations

Dec 15, 2015·Expert Review of Anticancer Therapy·N J Morley, D Marks
Apr 22, 2016·Current Treatment Options in Oncology·Nathan SinghShannon L Maude
Feb 28, 2016·Immunology Letters·Swati SikariaMojtaba Akhtari
Jun 14, 2016·The New England Journal of Medicine·Hagop M KantarjianAnjali S Advani
Aug 4, 2016·Genetic Testing and Molecular Biomarkers·Deniz Aslar OnerNejat Akar
Aug 16, 2016·Leukemia Research·Nosha Farhadfar, Mark R Litzow
Mar 30, 2017·Current Hematologic Malignancy Reports·Louise M ManMichael Keng
Jul 1, 2017·Blood Cancer Journal·T Terwilliger, M Abdul-Hay
Oct 4, 2016·Therapeutic Advances in Hematology·Nikolaos Papadantonakis, Anjali S Advani
Jul 27, 2017·Leukemia & Lymphoma·Ibrahim Aldoss, Anthony S Stein
Nov 25, 2017·Clinical Pharmacology and Therapeutics·Colleen E AnnesleyRebecca A Gardner
Feb 13, 2018·Proceedings of the National Academy of Sciences of the United States of America·Fabian MüllerIra Pastan
Mar 16, 2018·Biotechnology and Applied Biochemistry·Fatemeh FarajiMahdi Habibi-Anbouhi
Aug 6, 2018·Current Hematologic Malignancy Reports·Kathleen W Phelan, Anjali S Advani
Jul 31, 2018·American Journal of Hematology·Jaclyn RosenthalVinodh Pillai
Sep 14, 2018·Current Protocols in Cytometry·Sindhu Cherian, Maryalice Stetler-Stevenson
Dec 12, 2018·British Journal of Clinical Pharmacology·Jennifer E HibmaJoseph P Boni
Nov 22, 2018·Blood·Patrick BrownAndrea Biondi
Jul 30, 2019·Immunological Reviews·Elad JacobyNirali N Shah
Sep 27, 2019·Science Translational Medicine·Hong QinLarry W Kwak
May 29, 2019·The Cancer Journal·Francesco Ceppi, Rebecca A Gardner
Aug 30, 2020·Paediatric Drugs·Sylwia JasinskiWilliam L Carroll
Apr 8, 2020·Cancer Biotherapy & Radiopharmaceuticals·Urs B HagemannAlan S Cuthbertson
Nov 18, 2018·Current Hematologic Malignancy Reports·Franklin Fuda, Weina Chen
Dec 7, 2019·Hematology·Liora Schultz, Rebecca Gardner
Jun 29, 2017·Current Hematologic Malignancy Reports·Marlise R Luskin, Daniel J DeAngelo
Feb 9, 2020·Clinical and Translational Medicine·Candice Ashmore-Harris, Gilbert O Fruhwirth
Mar 7, 2019·Nature Reviews. Clinical Oncology·Nirali N Shah, Terry J Fry
Nov 26, 2020·American Journal of Clinical Pathology·Sindhu Cherian, Lorinda A Soma
May 22, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sneha RamakrishnaTerry J Fry
Mar 5, 2016·Molecular Cancer Therapeutics·Xiufen LiuIra Pastan
Apr 27, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Fabian MüllerIra Pastan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.